Skip to content

Effect of Real and Sham Acupoint Catgut Embedding on Psoriasis Vulgaris With Overweight/Obesity: A Pilot Study of Randomized Controlled Trial

Efficacy and Mechanism Exploration of Acupoint Catgut Embedding for Psoriasis Vulgaris with Overweight/Obesity

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004589
Enrollment
Unknown
Registered
2021-03-18
Start date
2021-04-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis Vulgaris With Overweight/Obesity

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine/The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The patient meets the diagnostic criteria of western medicine for psoriasis vulgaris and the diagnostic criteria of spleen deficiency dampness and blood stasis syndrome in Traditional Chinese Medicine; 2. The condition of patients is in a stationary phase; 3. PASI 1 to 10 and BSA =24 (kg/m2) or waist circumference: male >= 90cm, female >= 85cm; 5. Aged 18 to 65 years old; 6. Patients who voluntarily participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Articular, pustular, erythrodermal, drip, progressive psoriasis and psoriasis in specific sites, including face, scalp, fingernails, folds, glans, and palmoplantar; 2. Secondary overweight or obesity caused by hypothyroidism, polycystic ovary syndrome, insulinoma, hypercortisolism and drugs; 3. Women who are pregnant, lactating, or planning to become pregnant during the study period; 4. Patients with severe primary diseases such as circulatory, respiratory, digestive , urinary, endocrine and hematopoietic system, which cannot be controlled by conventional medication, patients with diabetes or tumor, and patients with severe infection, water, electrolyte and acid-base balance disorders. Or patients whose clinical test indicators is one of the following conditions: The increase of alanine aminotransferase or aspartate aminotransferase > 1.5 ULN; the increase of creatinine > 1.5 ULN; the increase of hemoglobin > 20g/L of ULN; the decrease of platelet count 5.5mmol/L or the decrease of blood potassium 50 or SDS > 53, or combined with other mental diseases; 10. Other conditions that the investigator deems inappropriate for participation in the study.

Design outcomes

Secondary

MeasureTime frame
Physician's Global Assessment;Waist Circumference;Body Weight;Body Mass Index;Waist-to-Hip Ratio;Response rate of PASI 90;Impact of Weight on Quality of Life-Lite;Dermatology Life Quality Index;Psoriasis Area and Severity Index;Visual Analog Scale;Response rate of PASI 75;Hip Crcumference;Psoriasis Vulgaris Symptoms Scale;

Primary

MeasureTime frame
Response rate of PASI 50;

Countries

China

Contacts

Public ContactChuan-Jian Lu

Guangdong Provincial Hospital of Chinese Medicine/The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

lcj@gzucm.edu.cn+86 13822250116

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026